Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Carrie E. Ryan(University at Buffalo, State University of New York), Davendra Sohal(University of Cincinnati), Jacob T. Lambdin(National Cancer Institute), Ralph C. Quillin(University of Cincinnati), Kristina Lemon(University of Cincinnati), Shimul A. Shah(University of Cincinnati Medical Center), Jonathan M. Hernandez(National Institutes of Health)
Cited by 3
Related Papers
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
Metastatic Pancreatic Cancer: ASCO Guideline Update
|Journal of Clinical Oncology|2020|287
Risk Factors and Consequences of Anastomotic Leak After Colectomy
|Diseases of the Colon & Rectum|2015|182
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
|Cancer|2011|97
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
|Annals of Oncology|2013|89